Measles, mumps and rubella vaccine 12 months after hematopoietic stem cell transplantation

Authors

  • Bruno Azevedo Randi Universidade de São Paulo, Faculdade de Medicina, Departamento de Moléstias Infecciosas e Parasitárias, São Paulo, São Paulo, Brazil http://orcid.org/0000-0002-6312-6669
  • Eder Gatti Fernandes Secretaria de Estado da Saúde de São Paulo, Coordenadoria de Controle de Doenças, Centro de Vigilância Epidemiológica “Prof. Alexandre Vranjac”, Divisão de Imunização, São Paulo, São Paulo, Brazil http://orcid.org/0000-0001-6907-7063
  • Hermes Ryoiti Higashino Universidade de São Paulo, Faculdade de Medicina, Departamento de Moléstias Infecciosas e Parasitárias, São Paulo, São Paulo, Brazil
  • Marta Heloisa Lopes Universidade de São Paulo, Faculdade de Medicina, Departamento de Moléstias Infecciosas e Parasitárias, São Paulo, São Paulo, Brazil
  • Vanderson Geraldo Rocha Universidade de São Paulo, Faculdade de Medicina, Departamento de Hematologia, Hemoterapia e Terapia Celular, São Paulo, São Paulo, Brazil
  • Silvia Figueiredo Costa Universidade de São Paulo, Faculdade de Medicina, Departamento de Moléstias Infecciosas e Parasitárias, São Paulo, São Paulo, Brazil, Universidade de São Paulo, Faculdade de Medicina, Hospital das Clínicas, Laboratório de Investigação Médica em Protozoologia, Bacteriologia e Resistência Antimicrobiana (LIM-49), São Paulo, São Paulo, Brazil, Universidade de São Paulo, Faculdade de Medicina, Instituto de Medicina Tropical de São Paulo, São Paulo, São Paulo, Brazil http://orcid.org/0000-0003-1087-752X
  • Ana Marli Christovam Sartori Universidade de São Paulo, Faculdade de Medicina, Departamento de Moléstias Infecciosas e Parasitárias, São Paulo, São Paulo, Brazil http://orcid.org/0000-0003-3777-0757

DOI:

https://doi.org/10.1590/S1678-9946202365021

Keywords:

Measles-mumps-rubella vaccine, MMR vaccine, Hematopoietic stem cell transplantation, Measles, Transplantation

Abstract

The measles, mumps and rubella (MMR) vaccine is usually recommended from 24 months after a hematopoietic stem cell transplant (HSCT). Some authors have demonstrated that the MMR vaccination can be safe from 12 months post-HSCT in non-immunosuppressed patients, as recommended by the Brazilian National Immunization Program/Ministry of Health, since 2006. The objectives of this study were to evaluate when patients received MMR vaccine after an HSCT in our care service and if there were reports of any side effects. We retrospectively reviewed the records of HSCT recipients who received at least one MMR dose in our care service, a quaternary teaching hospital in Sao Paulo city, Brazil, from 2017 to 2021. We identified 82 patients: 75.6% (90.1% in the autologous group and 45.1% in the allogeneic group) were vaccinated before 23 months post-transplantation. None reported side effects following the vaccination. Our data support that the MMR vaccination is safe from 12 to 23 months after HSCT.

Downloads

Download data is not yet available.

Downloads

Published

2023-03-22

Issue

Vol. 65 (2023)

Section

Brief Communication

License

Copyright (c) 2023 Bruno Azevedo Randi, Eder Gatti Fernandes, Hermes Ryoiti Higashino, Marta Heloisa Lopes, Vanderson Geraldo Rocha, Silvia Figueiredo Costa, Ana Marli Christovam Sartori

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

How to Cite

Randi, B. A. ., Fernandes, E. G. ., Higashino, H. R. ., Lopes, M. H., Rocha, V. G. ., Costa, S. F. ., & Sartori, A. M. C. . (2023). Measles, mumps and rubella vaccine 12 months after hematopoietic stem cell transplantation. Revista Do Instituto De Medicina Tropical De São Paulo, 65, e21. https://doi.org/10.1590/S1678-9946202365021